title: [Prolongation of enoxaparin therapy to one month promotes recanalization of the occlusively thrombosed deep veins].
abstract: OBJECTIVE
  To compare effects of prolongation of the treatment with therapeutic doses of enoxaparin to 1 month on recanalization of occlusively thrombosed deep veins (OTDV) of the limbs with results of standard therapy with unfractionated heparin (UFH). Both treatments were followed by warfarin administration.
  
  
  METHODS
  Thirty patients were selected from 111 patients with a history of deep vein thrombosis (DVT) and/or pulmonary artery embolism according to the following criteria: the presence of occlusive thrombosis of one deep vein minimum; the absence of DVT for 12 months of follow-up. Patients of group 1 (n = 15) received standard therapy (UFH for at least 5 days) with switch to warfarin. Patients of group 2 (n = 15) received therapeutic doses of enoxaparin (1 mg/kg each 12 hours) for 30 days minimum with switch to warfarin. Follow-up was 12 months. Ultrasonic duplex angioscanning of the limbs was made at baseline, 1, 3, 6 and 12 months after treatment start.
  
  
  RESULTS
  After follow-up month 1, 3 and 6 number of patients with occlusive DVT was significantly less in group 2. All the patients given enoxaparin achieved recanalization of OTDV within 3 months of treatment. OTDV recanalization was not achieved in 20% patients of group 1 even 12 months after treatment start.
  
  
  CONCLUSIONS
  Prolongation of enoxaparin treatment to 1 month followed by warfarin treatment is superior to standard UFH treatment followed by warfarin in providing recanalization of OTDV within 3 months of treatment. Moreover, this treatment predicts persistence of recanalization within 12 months of anticoagulant therapy.
authors.forename: N M
authors.initials: NM
authors.lastname: Vorob'eva
authors.forename: E P
authors.initials: EP
authors.lastname: Panchenko
authors.forename: O V
authors.initials: OV
authors.lastname: Ermolina
authors.forename: T V
authors.initials: TV
authors.lastname: Balakhonova
authors.forename: A B
authors.initials: AB
authors.lastname: Dobrovol'skiĭ
authors.forename: E V
authors.initials: EV
authors.lastname: Titaeva
authors.forename: Z B
authors.initials: ZB
authors.lastname: Khasanova
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Postnov
authors.forename: A I
authors.initials: AI
authors.lastname: Kirienko
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D017984:Enoxaparin / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011655:Pulmonary Embolism / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D014859:Warfarin / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin; D014859:Warfarin